| Cardiovascular Risk Management |
1 |
1 |
| Hypogonadism |
0 |
0.95 |
| Testosterone |
0 |
0.99 |
| Testosterone Therapy |
0 |
0.77 |
| Low Testosterone |
0 |
0.72 |
| Meta-Analysis |
0 |
0.3 |
| Lipids Management |
0 |
0.29 |
| Thromboembolism |
0 |
0.28 |
| Cerebrovascular Accident |
0 |
0.25 |
| Myocardial Infarction (MI) |
0 |
0.25 |
| Arrhythmia |
0 |
0.2 |
| Heart Failure (HF) |
0 |
0.18 |
| Infarction |
0 |
0.11 |
| Coronary Artery Disease (CAD) |
0 |
0.08 |
| Heart |
0 |
0.08 |
| Angina Pectoris |
0 |
0.06 |
| Atherosclerosis |
0 |
0.06 |
| Blood |
0 |
0.06 |
| Board Certification |
0 |
0.06 |
| Erectile Dysfunction |
0 |
0.06 |
| Food and Drug Administration (FDA) |
0 |
0.06 |
| Grant |
0 |
0.06 |
| Obesity |
0 |
0.06 |
| Osteoporosis |
0 |
0.06 |
| Patient Safety |
0 |
0.06 |
| High Density Lipoprotein (HDL) cholesterol |
0 |
0.05 |
| Adverse Effects |
0 |
0.03 |
| Anemia |
0 |
0.03 |
| Body Mass Index |
0 |
0.03 |
| California |
0 |
0.03 |
| Dyslipidemia |
0 |
0.03 |
| Edema |
0 |
0.03 |
| Endocrine Society |
0 |
0.03 |
| Europe |
0 |
0.03 |
| Fellowship |
0 |
0.03 |
| Georgia |
0 |
0.03 |
| Hand |
0 |
0.03 |
| Hematocrit |
0 |
0.03 |
| Insulin Resistance |
0 |
0.03 |
| Muscle |
0 |
0.03 |
| Sexual Dysfunction |
0 |
0.03 |
| Venous Thromboembolism (VTE) |
0 |
0.03 |